Crosslink Therapeutics Inc. filed a Form D with the Securities and Exchange Commission on 2026-10-20.
Crosslink Therapeutics Inc. filed a Form D notice of an exempt securities offering with the SEC on October 20, 2026. The filing reports $5.50M sold. Its industry group is Pharmaceuticals. It names Ronald Seidel, III (Executive Officer, Director), Andrew King (Director), Lou Tartaglia (Director) (SEC Form D, October 20, 2026).
Sell to companies like Crosslink Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-10-20 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Crosslink Therapeutics Inc.
Free to see. No signup.
More on the people and the money behind Crosslink Therapeutics Inc., from the filings we hold.
Pharmaceuticals raises by companies based in Massachusetts, filed within 90 days of this one, largest first.
Get an email when Crosslink Therapeutics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Crosslink Therapeutics Inc. raises, hires or launches. No email unless you switch it on.
Watch Crosslink Therapeutics Inc. →Get the full cited report on Crosslink Therapeutics Inc.
What the filing shows about Crosslink Therapeutics Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Crosslink Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for Crosslink Therapeutics Inc. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Crosslink Therapeutics Inc. See pricing
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 157 filings in Pharmaceuticals, totalled by week. The dot is this raise, $5.50M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Ronald Seidel, III is named as Executive Officer and Director on the Form D that Crosslink Therapeutics Inc. filed with the SEC on 20 October 2026, one of 6 people that filing names.
Andrew King is named as Director on the Form D that Crosslink Therapeutics Inc. filed with the SEC on 20 October 2026, one of 6 people that filing names.
Lou Tartaglia is named as Director on the Form D that Crosslink Therapeutics Inc. filed with the SEC on 20 October 2026, one of 6 people that filing names.
Rodolfo Chaparro is named as Director on the Form D that Crosslink Therapeutics Inc. filed with the SEC on 20 October 2026, one of 6 people that filing names.
David Fallace is named as Director on the Form D that Crosslink Therapeutics Inc. filed with the SEC on 20 October 2026, one of 6 people that filing names.
Cameron Gallagher is named as Director on the Form D that Crosslink Therapeutics Inc. filed with the SEC on 20 October 2026, one of 6 people that filing names.
6 people named on the filing — 1 holding an executive role and 5 as directors only.
Named as of the 2026-10-20 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Crosslink Therapeutics Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Crosslink Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Crosslink Therapeutics Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Crosslink Therapeutics Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Crosslink Therapeutics Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Crosslink Therapeutics Inc.. With no account yet, you sign up free and land on the result.
On these lists: Boston raises, week of 2026-10-19 · Pharmaceuticals raises in Boston
https://mentionfox.com/funding/crosslink-therapeutics-inc-form-d-000002